Department of Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.
Sultan Qaboos Univ Med J. 2023 Aug;23(3):380-386. doi: 10.18295/squmj.1.2023.009. Epub 2023 Aug 28.
This study aimed to reduce the intensity of myoclonus movements by comparing the effectiveness of granisetron and sufentanil in reducing the intensity of etomidate-induced myoclonic movements. Etomidate-induced myoclonus occurs in up to 85% of patients under general anaesthesia. This type of myoclonus can induce significant clinical and economic problems in patients with special conditions.
This double-blind randomised clinical trial study consisted of 96 adult patients recruited between January and July 2021 from Mashhad University of Medical Sciences, Mashhad, Iran. Using block randomisation, subjects were divided into three groups of 32 patients: the group receiving granisetron 40 μg/kg (group G), the group receiving sufentanil 0.2 μg/kg (group S) and the control group who did not receive the pretreatment (group C). Patients received these medications as pretreatments 120 seconds before induction with etomidate. After the injection of etomidate with a dose of 0.3 mg/kg, the incidence of myoclonus was evaluated. After evaluating the myoclonus, the full dose of narcotics (fentanyl 1 μg/kg) and muscle relaxants (atracurium 0.5 mg/kg) were administered to patients and a suitable airway was established for them.
The findings indicated that granisetron reduced the intensity and incidence of myoclonic movements more than sufentanil. In addition, myoclonic movements were observed at a significantly higher intensity in the control group ( = 0.001).
The results obtained from the current study indicate that granisetron and sufentanil as pretreatments are effective for reducing myoclonus in patients.
本研究旨在通过比较格拉司琼和舒芬太尼对减少依托咪酯诱发肌阵挛的作用来降低肌阵挛运动的强度。依托咪酯诱导的肌阵挛在全身麻醉下的患者中高达 85%。这种类型的肌阵挛在特殊情况下的患者中会引起显著的临床和经济问题。
本双盲随机临床试验研究纳入了 2021 年 1 月至 7 月间来自伊朗马什哈德医科大学的 96 名成年患者。采用区组随机化方法,将受试者分为三组,每组 32 名患者:接受格拉司琼 40μg/kg(G 组)、接受舒芬太尼 0.2μg/kg(S 组)和未接受预处理的对照组(C 组)。患者在接受依托咪酯诱导前 120 秒接受这些药物预处理。在给予依托咪酯 0.3mg/kg 后,评估肌阵挛的发生情况。在评估肌阵挛后,给患者给予全剂量的麻醉药物(芬太尼 1μg/kg)和肌肉松弛剂(阿曲库铵 0.5mg/kg),并为他们建立合适的气道。
研究结果表明,格拉司琼比舒芬太尼更能降低肌阵挛的强度和发生率。此外,对照组的肌阵挛运动强度明显更高(=0.001)。
本研究结果表明,格拉司琼和舒芬太尼作为预处理可有效减少患者的肌阵挛。